Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study
Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI) acquired resistance was an inevitably events in NSCLC treatment. Aims Intending to overcome the acquired resistance of EGFR‐TKI. Materials & Methods A clinical trial was, we enrolled 12 patients who were s...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6737 |
| _version_ | 1797371914332667904 |
|---|---|
| author | Minghui Liu Xin Li Hongbing Zhang Fan Ren Jinghao Liu Yongwen Li Ming Dong Honglin Zhao Song Xu Hongyu Liu Jun Chen |
| author_facet | Minghui Liu Xin Li Hongbing Zhang Fan Ren Jinghao Liu Yongwen Li Ming Dong Honglin Zhao Song Xu Hongyu Liu Jun Chen |
| author_sort | Minghui Liu |
| collection | DOAJ |
| description | Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI) acquired resistance was an inevitably events in NSCLC treatment. Aims Intending to overcome the acquired resistance of EGFR‐TKI. Materials & Methods A clinical trial was, we enrolled 12 patients who were slowly progressing on first‐generation EGFR‐TKI, and added apatinib when the patients got slow progression. Results Seven patients were included in the efficacy analysis. The median PFS2 of apatinib combined with EGFR‐TKI was 8.2 months (95% CI, 7.3 m‐NA), and the total PFS reached 20.9 months (95% CI, 17.3 m‐NA) when plus PFS1. All the adverse events were manageable. The median PFS was significantly longer for circulating tumor DNA (ctDNA)‐cleared patients (8.4 months; 95% CI, 8.2‐NA) than for those ctDNA not cleared (7.1 months; 95% CI, 6.9‐NA) (p = 0.0082). Discussion The addition of apatinib did improve the duration of first‐generation EGFR‐TKI use, and the duration was better than the first‐line use of third‐generation EGFR‐TKI. Conclusion The addition of apatinib when the patients got slow progression after initial EGFR‐TKI therapy may be a good treatment option and the side effects are controllable. It is possible to monitor treatment efficacy using ctDNA. |
| first_indexed | 2024-03-08T18:28:48Z |
| format | Article |
| id | doaj.art-750afa4493734bcaabe47594c07f1a19 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-08T18:28:48Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-750afa4493734bcaabe47594c07f1a192023-12-30T08:53:25ZengWileyCancer Medicine2045-76342023-12-011224217352174110.1002/cam4.6737Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm studyMinghui Liu0Xin Li1Hongbing Zhang2Fan Ren3Jinghao Liu4Yongwen Li5Ming Dong6Honglin Zhao7Song Xu8Hongyu Liu9Jun Chen10Department of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaDepartment of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaDepartment of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaDepartment of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaDepartment of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital Tianjin ChinaDepartment of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaDepartment of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaDepartment of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital Tianjin ChinaDepartment of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin People's Republic of ChinaAbstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI) acquired resistance was an inevitably events in NSCLC treatment. Aims Intending to overcome the acquired resistance of EGFR‐TKI. Materials & Methods A clinical trial was, we enrolled 12 patients who were slowly progressing on first‐generation EGFR‐TKI, and added apatinib when the patients got slow progression. Results Seven patients were included in the efficacy analysis. The median PFS2 of apatinib combined with EGFR‐TKI was 8.2 months (95% CI, 7.3 m‐NA), and the total PFS reached 20.9 months (95% CI, 17.3 m‐NA) when plus PFS1. All the adverse events were manageable. The median PFS was significantly longer for circulating tumor DNA (ctDNA)‐cleared patients (8.4 months; 95% CI, 8.2‐NA) than for those ctDNA not cleared (7.1 months; 95% CI, 6.9‐NA) (p = 0.0082). Discussion The addition of apatinib did improve the duration of first‐generation EGFR‐TKI use, and the duration was better than the first‐line use of third‐generation EGFR‐TKI. Conclusion The addition of apatinib when the patients got slow progression after initial EGFR‐TKI therapy may be a good treatment option and the side effects are controllable. It is possible to monitor treatment efficacy using ctDNA.https://doi.org/10.1002/cam4.6737apatinibcirculating tumor DNAEGFR‐TKINSCLCsafety |
| spellingShingle | Minghui Liu Xin Li Hongbing Zhang Fan Ren Jinghao Liu Yongwen Li Ming Dong Honglin Zhao Song Xu Hongyu Liu Jun Chen Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study Cancer Medicine apatinib circulating tumor DNA EGFR‐TKI NSCLC safety |
| title | Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study |
| title_full | Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study |
| title_fullStr | Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study |
| title_full_unstemmed | Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study |
| title_short | Apatinib added when NSCLC patients get slow progression with EGFR‐TKI: A prospective, single‐arm study |
| title_sort | apatinib added when nsclc patients get slow progression with egfr tki a prospective single arm study |
| topic | apatinib circulating tumor DNA EGFR‐TKI NSCLC safety |
| url | https://doi.org/10.1002/cam4.6737 |
| work_keys_str_mv | AT minghuiliu apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT xinli apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT hongbingzhang apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT fanren apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT jinghaoliu apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT yongwenli apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT mingdong apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT honglinzhao apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT songxu apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT hongyuliu apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy AT junchen apatinibaddedwhennsclcpatientsgetslowprogressionwithegfrtkiaprospectivesinglearmstudy |